Literature DB >> 12776222

Therapeutic strategies for rheumatoid arthritis.

Josef S Smolen1, Günter Steiner.   

Abstract

Recent years have seen considerable advances in our understanding of both the clinical and basic-research aspects of rheumatoid arthritis. Clinical progress has come from a better recognition of the natural history of the disease, the development and validation of outcome measures for clinical trials and, consequently, innovative trial designs. In parallel, basic research has provided clues to the pathogenic events underlying rheumatoid arthritis, and advances in biotechnology have facilitated the development of new classes of therapeutics. Here, we summarize the fruits of these advances: innovative approaches to the use of existing, traditional disease-modifying antirheumatic drugs; novel agents approved very recently; and further avenues that are presently under investigation or which are of more distant promise.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776222     DOI: 10.1038/nrd1109

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  196 in total

1.  An assessment of ocular elasticity using real time ultrasound and ocular response analyzer in active or remission rheumatoid arthritis.

Authors:  Mehmet Erol Can; Özlem Unal; Meltem Ece Kars; Sukran Erten; Gamze Dereli Can; Necati Duru; Nurullah Cagil
Journal:  Int Ophthalmol       Date:  2018-12-03       Impact factor: 2.031

Review 2.  [Drug therapy of rheumatoid arthritis].

Authors:  U Arndt; M Rittmeister; B Möller
Journal:  Orthopade       Date:  2003-12       Impact factor: 1.087

Review 3.  B cells: new ways to inhibit their function in rheumatoid arthritis.

Authors:  Robert H Carter
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 4.  B cell signalling as therapeutic target.

Authors:  R H Carter
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 5.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

6.  Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis.

Authors:  Elke Kunisch; Muktheshwar Gandesiri; Reneé Fuhrmann; Andreas Roth; Rando Winter; Raimund W Kinne
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

7.  Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.

Authors:  Masashi Miyazaki; Yosuke Fujikawa; Chikahiro Takita; Hiroshi Tsumura
Journal:  Clin Rheumatol       Date:  2006-04-04       Impact factor: 2.980

8.  The TRAIL to arthritis.

Authors:  George C Tsokos; Maria Tsokos
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

9.  Modulation of Th1 cytokines and inflammatory mediators by Euphorbia hirta in animal model of adjuvant-induced arthritis.

Authors:  Sheikh Fayaz Ahmad; Phalisteen Sultan; Abdelkader E Ashour; Tajdar Husain Khan; Sabry M Attia; Saleh A Bakheet; Adel R A Abd-Allah
Journal:  Inflammopharmacology       Date:  2012-12-11       Impact factor: 4.473

Review 10.  Beyond oncology--application of HPMA copolymers in non-cancerous diseases.

Authors:  Xin-Ming Liu; Scott C Miller; Dong Wang
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.